ଭିସମୋଡେଗିବ

ଭିସମୋଡେଗିବ
Clinical data
Pronunciation	Vismodegib /ˌvɪsmoʊˈdɛɡɪb/ VIS-moh-DEG-ib; Erivedge /ˈɛrɪvɛdʒ/ ERR-i-vej
Trade names	Erivedge
Synonyms	GDC-0449, RG-3616
AHFS/Drugs.com	monograph
data	EU EMA: yes; US FDA: Vismodegib;
Pregnancy; category	AU: X (High risk) ; US: X (Contraindicated) ; ;
Routes of; administration	By mouth (capsules)
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Bioavailability	31.8%
Protein binding	>99%
Metabolism	<2% metabolised by CYP2C9, CYP3A4, CYP3A5
Elimination half-life	4 days (continuous use),; 12 days (single dose)
Excretion	Fecal (82%), Urinary (4.4%)
Identifiers
	IUPAC name 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide;
ECHA InfoCard	100.234.019
Chemical and physical data
Formula	C19H14Cl2N2O3S
Molar mass	୪୨୧.୨୯ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;
	InChI InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24); Key:BPQMGSKTAYIVFO-UHFFFAOYSA-N;

ଭିସମୋଡେଗିବ (ଇଂରାଜୀ ଭାଷାରେ Vismodegib), ଏରିଭେଜ୍ ଏହାର ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ବାସାଲ ସେଲ କର୍କଟ (ବିସିସି) ରୋଗରର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୨] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ସେହିମାନଙ୍କ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ଯେଉଁମାନଙ୍କଠାରେ କର୍କଟ ବ୍ୟାପିଛି କିମ୍ବା ପୁନରାବୃତ୍ତି ହୋଇଛି ଏବଂ ଅନ୍ୟ ପଦ୍ଧତି ଦ୍ୱରା ଚିକିତ୍ସା ସମ୍ଭବ ନୁହେଁ ।^[୨] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ କେଶ ଝଡ଼ିବା, ଥକାପଣ, ଅଇ, ଏବଂ ସାମୟିକ ମାଂସପେଶୀ ସଂକୋଚନ ବା ସ୍ପାଜ୍ମ ହୋଇପାରେ ।^[୨] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୨] ଉଭୟ ପୁରୁଷ ଏବଂ ମହିଳାଙ୍କ ପାଇଁ ପ୍ରଭାବଶାଳୀ ଜନ୍ମ ନିୟନ୍ତ୍ରଣ ସୁପାରିଶ କରାଯାଏ ।^[୨] ଏହା ଏକ ହେଜ‌ହୋଗ ପଥ ପ୍ରତିରୋଧକ ।^[୩]

୨୦୧୨ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୧୩ରେ ୟୁରୋପରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଭିସମୋଡେଗିବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୨] ^[୪] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ସୁଦ୍ଧା ଏହା ପିଛା ମାସକୁ ପ୍ରାୟ ୧୨,୩୦୦ ଡଲାର ଖର୍ଚ୍ଚ ହୋଇଥାଏ ଏବଂ ଏହା କେବଳ ବିଶେଷ ଫର୍ମାସି ମାଧ୍ୟମରେ ଉପଲବ୍ଧ ।^[୨] ^[୫] ଯୁକ୍ତରାଜ୍ୟରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୬,୩୦୦ ପାଉଣ୍ଡ ।^[୩]

ଆଧାର

↑ ^୧.୦ ^୧.୧ FDA Professional Drug Information
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ ^୨.୭ "Vismodegib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 22 March 2016. Retrieved 15 September 2021.
↑ ^୩.୦ ^୩.୧ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1066. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
↑ "Erivedge". Archived from the original on 13 August 2021. Retrieved 16 September 2021.
↑ "Erivedge Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 5 September 2015. Retrieved 16 September 2021.

[dpe-1] ୧.୦ ^୧.୧ FDA Professional Drug Information

[AHFS2021-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ ^୨.୭ "Vismodegib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 22 March 2016. Retrieved 15 September 2021.

[BNF80-3] ୩.୦ ^୩.୧ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1066. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[EPAR2021-4] "Erivedge". Archived from the original on 13 August 2021. Retrieved 16 September 2021.

[5] "Erivedge Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 5 September 2015. Retrieved 16 September 2021.

[୨]

[୧]

[୩]

[୪]

[୫]

Clinical data

Pronunciation	Vismodegib /ˌvɪsmoʊˈdɛɡɪb/ VIS-moh-DEG-ib Erivedge /ˈɛrɪvɛdʒ/ ERR-i-vej
Trade names	Erivedge
Synonyms	GDC-0449, RG-3616
AHFS/Drugs.com	monograph
data	EU EMA: yes US FDA: Vismodegib
Pregnancy category	AU: X (High risk) ^[୧] US: X (Contraindicated) ^[୧]
Routes of administration	By mouth (capsules)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) US: ℞-only EU: Rx-only
Pharmacokinetic data
Bioavailability	31.8%
Protein binding	>99%
Metabolism	<2% metabolised by CYP2C9, CYP3A4, CYP3A5
Elimination half-life	4 days (continuous use), 12 days (single dose)
Excretion	Fecal (82%), Urinary (4.4%)
Identifiers
IUPAC name 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide
ECHA InfoCard	100.234.019
Chemical and physical data
Formula	C₁₉H₁₄Cl₂N₂O₃S
Molar mass	୪୨୧.୨୯ g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl
InChI InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24) Key:BPQMGSKTAYIVFO-UHFFFAOYSA-N